Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Corp to present Alzheimer’s research data at Paris conference

Summit Corp to present Alzheimer’s research data at Paris conference

Drug discovery group Summit Corporation PLC (LON:SUMM) said it is presenting the recently reported positive results from its programme targeting Alzheimer's disease and other neurological disorders at the Alzheimer's Association International Conference 2011 (ICAD 2011) which is currently being held in Paris.

Alzheimer's is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia.  It remains an area of high unmet medical need with current treatment options only providing symptomatic relief. 

The presentation will highlight Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase).

The company identifid and then optimised the generation of extremely potent, selective and non-cytotoxic inhibitors of OGA using its Seglin technology drug discovery platform.

Summit will also demonstrate in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.

Interest in the Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications, Summit said.

“As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease,” it added.

View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

biotech_564b2dac17b4d.jpg
November 17 2015
Biotech Summit Therapeutics (LON:SUMM is edging closer to a huge 'inflection point', which could potentially transform its fortunes.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
Blood test
Tue
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.